Pluristem adds South Korea to list of countries participating in IC study

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI) gets South Korean regulatory approval to conduct a Phase 2 study of PLX-PAD cells in Intermittent Claudication.

South Korea is the fourth country to participate in the multinational trial. (PR)